Butyric Acid

Butyric Acid

SCHEMBL2807771

CCCC(=O)O.CCCC(=O)O.CCCCCC

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.81
HDAC3 O15379 1/20 0.81
HDAC1 Q13547 1/20 0.81
HDAC2 Q92769 1/20 0.81
HDAC8 Q9BY41 1/20 0.81
AKR1B1 P15121 1/20 0.78
GPR84 Q9NQS5 7/20 0.74
PPARG P37231 7/20 0.74
PPARD Q03181 7/20 0.74
PPARA Q07869 7/20 0.74
HDAC11 Q96DB2 5/20 0.74
TSHR P16473 4/20 0.74
PTPN1 P18031 3/20 0.74
FABP4 P15090 3/20 0.74
ALDH1A1 P00352 2/20 0.74
TLR2 O60603 2/20 0.74
TDP1 Q9NUW8 2/20 0.74
KMT2A Q03164 2/20 0.74
ALOX15 P16050 2/20 0.74
HSD17B10 Q99714 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL8661684 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL4523506 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL4229756 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL6418455 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL7471228 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL23014527 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL3077105 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL7462002 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL59956 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL4523509 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
US-20140228310-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2014-08-14 US disclosed
US-8741936-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2014-06-03 US disclosed
US-20120258924-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2012-10-11 US disclosed
US-20100240704-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2010-09-23 US disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
EP-1945606-A1 ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF Korea Research Institute of Chemical Technology (KR) 2008-07-23 EP disclosed
WO-2007052938-A1 ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-05-10 WO disclosed
US-20060270612-A1 Method of modulating stress-activated protein kinase system INTERMUNE, INC. 2006-11-30 US disclosed
EP-0802915-B1 CAMPTOTHECIN DERIVATIVES AND ITS MANUFACTURING METHOD CHONG KUN DANG CORP (KR) 2002-12-04 EP disclosed
EP-0802915-A1 CAMPTOTHECIN DERIVATIVES AND ITS MANUFACTURING METHOD CHONG KUN DANG CORP (KR) 1997-10-29 EP disclosed
WO-1996021666-A1 CAMPTOTHECIN DERIVATIVES AND ITS MANUFACTURING METHOD CHONG KUN DANG CORPORATION (KR) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240704-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885
US-10010536-B2 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885
US-20140228310-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885
US-20120258924-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885
US-20060270612-A1 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 FFAR3 3556/4885HDAC3 881/4885HDAC1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.